Joseph Boyle is a British Heart Foundation Senior Clinical Research Fellow in the Vascular Sciences section, National Heart and Lung Institute.
Dr Boyle qualified in Pharmacology (Class I Hons, 1988) and Medicine (with Hons, 1991) from the University of Glasgow, in the top few in the year. Work as a junior doctor witnessing fatal cardiovascular disease inspired a career in cardiovascular pathology. He then moved to the University of Cambridge and did a PhD on mechanisms of macrophage-induced vascular smooth muscle cell apoptosis with Professors Peter Weissberg and Martin Bennett and Dr David Bowyer.
He is fully clinically trained in histopathology, mainly at Cambridge, and specialised in cardiovascular, renal and pulmonary pathology. He then moved to Hammersmith Hospital, Imperial College London for six years as a full-time consultant pathologist with an interest in renal / cardiovascular pathology.
Dr Boyle’s research focus is in connecting the functional genomics of macrophage differentiation with clinical cardiovascular and renal pathology with a view to improved pharmacology.
Dr Boyle became a BHF Intermediate Clinical Research Fellow with Professor Dorian Haskard working on novel macrophage inactivation pathways, initially discovered in intraplaque haemorrhage in the coronary arteries of patients with fatal acute coronary syndrome. These evoke macrophages with decreased inflammatory activation, a phenotype we termed Mhem.
This work identified a new transcriptional pathway driven by ATF1, allowing coordination between iron recycling, cholesterol recycling and anti-inflammatory effects in macrophages after haemorrhage. This has exciting implications for treatment, especially since we have now found that it can also be stimulated by the diabetic agent metformin via AMP-Kinase.
Dr Boyle then honed his diagnostic skills at Papworth Hospital Cambridge before coming back to Imperial as a BHF Senior Clinical Research Fellow to develop mechanistic and translational studies of the AMPK-ATF1-Mhem pathway. Dr Boyle now heads the growing Macrophage Differentiation research group. Applications from potential PhD students interested in molecular mechanisms of erythrocyte recycling, or in cardiometabolic disease in metformin-treated patients are particularly welcome.
et al., 2009, Coronary Intraplaque Hemorrhage Evokes a Novel Atheroprotective Macrophage Phenotype, American Journal of Pathology, Vol:174, ISSN:0002-9440, Pages:1097-1108
et al., 2011, Heme Induces Heme Oxygenase 1 via Nrf2 Role in the Homeostatic Macrophage Response to Intraplaque Hemorrhage, Arteriosclerosis Thrombosis and Vascular Biology, Vol:31, ISSN:1079-5642, Pages:2685-U826
et al., 2012, Activating Transcription Factor 1 Directs Mhem Atheroprotective Macrophages Through Coordinated Iron Handling and Foam Cell Protection, Circulation Research, Vol:110, ISSN:0009-7330, Pages:20-33
et al., 2013, 5 '-AMP-Activated Protein Kinase-Activating Transcription Factor 1 Cascade Modulates Human Monocyte-Derived Macrophages to Atheroprotective Functions in Response to Heme or Metformin, Arteriosclerosis Thrombosis and Vascular Biology, Vol:33, ISSN:1079-5642, Pages:2470-2480